NCT03833167 2026-03-10
KEYNOTE-630
Merck Sharp & Dohme LLC
Phase 3 Completed
Clinical Trials
20 trialsNCT03976362 2026-02-25
KEYLYNK-008
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04150900 2026-02-19
1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck
University of Maryland, Baltimore
Phase 2 Active not recruiting
NCT04260529 2026-01-29
CICILIA
Cytovation AS
Phase 1/2 Completed
NCT05383170 2025-11-28
Catalyst
Cytovation AS
Phase 1/2 Completed
NCT02959437 2025-10-21
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
Incyte Corporation
Phase 1/2 Terminated
NCT04418661 2025-05-29
Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies
Sanofi
Phase 1/2 Terminated
NCT04808999 2025-05-29
Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)
University of Pittsburgh
Phase 2 Active not recruiting
NCT04812535 2025-02-11
Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.
InflaRx GmbH
Phase 2 Terminated
NCT02723955 2024-12-27
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
GlaxoSmithKline
Phase 1 Completed
NCT03447314 2024-09-23
Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT03416335 2024-05-30
A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
Sumitomo Pharma America, Inc.
Phase 1/2 Terminated
NCT03396471 2024-04-18
Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary
Hoosier Cancer Research Network
Phase 2 Terminated
NCT03997448 2024-02-20
Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149
Big Ten Cancer Research Consortium
Phase 2 Terminated
NCT03308942 2023-10-16
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
Tesaro, Inc.
Phase 2 Completed
NCT02501096 2023-07-20
A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors
Eisai Inc.
Phase 1/2 Completed
NCT02904226 2023-07-03
ICONIC
Jounce Therapeutics, Inc.
Phase 1/2 Completed
NCT04800627 2022-12-27
Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT01848834 2021-06-28
MK-3475-012
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT02303990 2021-05-12
RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers
Abramson Cancer Center at Penn Medicine
Phase 1 Completed